PMID- 38023119
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231201
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Analysis of the risk factors of radiation pneumonitis in patients after 
      radiotherapy for esophageal squamous cell carcinoma.
PG  - 1198872
LID - 10.3389/fonc.2023.1198872 [doi]
LID - 1198872
AB  - OBJECTIVE: To predict the risk factors of radiation pneumonitis (RP) in patients 
      with esophageal squamous cell carcinoma (ESCC) who received radiotherapy. 
      METHODS: From January 2015 to October 2021, 477 ESCC patients were enrolled and 
      were assessed retrospectively. All these patients received radiotherapy for 
      primary lesions or mediastinal metastatic lymph nodes. Clinical efficacy and 
      adverse events (AEs) were observed. Univariate analysis identified clinical and 
      dosimetric factors associated with the development of RP, and multivariate 
      logistic regression analysis identified independent potential risk factors 
      associated with the development of RP. Nomograms were constructed to predict RP 
      based on the results of multivariate logistic regression analysis. RESULTS: Among 
      the 477 ESCC patients, the incidence of RP was 22.2%, and the incidence of grade 
      4 or higher RP was 1.5%. Univariate analysis indicated that chronic obstructive 
      pulmonary disease (COPD), pulmonary infection, leucopenia, PTV volume, V5, V20, 
      V30 and MLD affected the occurrence of RP. The multivariate logistic regression 
      analysis indicated that COPD (OR:1.821, 95%CI:1.111-2.985; P=0.017), pulmonary 
      infection (OR:2.528, 95%CI:1.530-4.177; P<0.001), higher V20 (OR: 1.129, 95% 
      CI:1.006-1.266; P=0.029) were significant independent predictors of RP in ESCC 
      patients. COPD, pulmonary infection, V20 have been integrated for the RP 
      nomogram. The rate of RP was significantly reduced in the V20<21.45% group. 
      Further analysis indicated that the old age, diabetes, higher V20, and higher MLD 
      were risk factors for grade 4 or higher RP. The area under the curve (AUC) value 
      for V20 was 0.73 (95% CI, 0.567-0.893, P < 0.05). CONCLUSION: We have determined 
      the risk factors of RP and grade 4 or higher RP in ESCC patients after 
      radiotherapy. MLD, V20, COPD were independent factors for RP. It was necessary to 
      take measures to reduce or avoid the occurrence of RP for patients with these 
      risk factors at the early stage.
CI  - Copyright (c) 2023 Sun, Wang, Zhu, Chen, Chen, Qiu and Wu.
FAU - Sun, Lu
AU  - Sun L
AD  - Department of Radiation Oncology, the People's Hospital Affiliated to Jiangsu 
      University, Zhenjiang, Jiangsu, China.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Radiation Oncology, the People's Hospital Affiliated to Jiangsu 
      University, Zhenjiang, Jiangsu, China.
FAU - Zhu, Lihua
AU  - Zhu L
AD  - Department of Radiation Oncology, the People's Hospital Affiliated to Jiangsu 
      University, Zhenjiang, Jiangsu, China.
FAU - Chen, Jun
AU  - Chen J
AD  - Department of Radiation Oncology, the People's Hospital Affiliated to Jiangsu 
      University, Zhenjiang, Jiangsu, China.
FAU - Chen, Zhifu
AU  - Chen Z
AD  - Department of Radiation Oncology, the People's Hospital Affiliated to Jiangsu 
      University, Zhenjiang, Jiangsu, China.
FAU - Qiu, Zhiyuan
AU  - Qiu Z
AD  - Department of Oncology, the People's Hospital Affiliated to Jiangsu University, 
      Zhenjiang, Jiangsu, China.
FAU - Wu, Chaoyang
AU  - Wu C
AD  - Department of Radiation Oncology, the People's Hospital Affiliated to Jiangsu 
      University, Zhenjiang, Jiangsu, China.
LA  - eng
PT  - Journal Article
DEP - 20231107
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10662299
OTO - NOTNLM
OT  - V20
OT  - dose-volume-histogram
OT  - esophageal squamous cell carcinoma (ESCC)
OT  - radiation pneumonitis (RP)
OT  - risk factors
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/11/29 18:42
MHDA- 2023/11/29 18:43
PMCR- 2023/01/01
CRDT- 2023/11/29 15:40
PHST- 2023/04/02 00:00 [received]
PHST- 2023/10/24 00:00 [accepted]
PHST- 2023/11/29 18:43 [medline]
PHST- 2023/11/29 18:42 [pubmed]
PHST- 2023/11/29 15:40 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1198872 [doi]
PST - epublish
SO  - Front Oncol. 2023 Nov 7;13:1198872. doi: 10.3389/fonc.2023.1198872. eCollection 
      2023.